Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry 2020 Annual Meeting

Zynerba Pharmaceuticals

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting.

The oral presentations will take place during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session. The AACAP annual meeting is being held virtually from October 12th through October 24th, 2020. A copy of the slides will be made available on Friday, October 23rd at the time of presentation on the Zynerba corporate website at http://zynerba.com/publications/.

“We are honored to be invited to provide two oral presentations at the virtual AACAP annual meeting to further describe the important responses to Zygel observed in clinical trials in children and adolescents with Fragile X syndrome (FXS) and autism spectrum disorder (ASD), respectively, including data reported by parents and caregivers,” said Joseph Palumbo, MD, FAPA, MACPsych, Chief Medical Officer of Zynerba. “On behalf of participating families and investigators, we look forward to sharing these results with the AACAP scientific community.”

READ:  Trevena Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting

Friday, October 23rd, 2020 from 2:00 to 4:00 PM EDT

Title: “ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and as a Prognostic Biomarker”
Session: “Research Pipeline: New Findings on Diagnostic and Therapeutics”
Presentation number: 32.8

Title: “Tolerability and Efficacy of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study [BRIGHT (ZYN2-CL-030)]”
Session: “Research Pipeline: New Findings on Diagnostic and Therapeutics”
Presentation number: 32.7

Zynerba Pharmaceuticals, headquartered in Devon, PA, is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments